Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 7, 2020

FDA clears Abbott’s Gallant devices for cardiac arrhythmia

Abbott has received the US Food and Drug Administration (FDA) approval for its Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices.

Abbott has received the US Food and Drug Administration (FDA) approval for its Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices.

The new Gallant system offers Bluetooth capability and pairs with the company’s myMerlinPulse, an iOS and Android-compatible smartphone app.

The features help to optimise patient engagement and streamline communications between doctors and their patients, the company noted.

myMerlinPulse app also helps in earlier intervention by allowing continuous remote monitoring. It reduces clinical burden by enabling physicians to identify asymptomatic episodes and patient-triggered transmissions.

Additionally, the app helps patients to take an active role in their healthcare by providing them with access to data, device performance and transmission history.

The new defibrillators also offer battery longevity and magnetic resonance imaging (MRI) compatibility to patients with heart rhythm disorders.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Approximately 6.1 million people in the US suffer from cardiac arrhythmias or abnormal heart rhythms.

ICDs are used to reduce the risks of life-threatening arrhythmias, while CRT-Ds can be used to restore the heart’s natural pattern of beating in patients with heart failure.

Abbott Cardiac Rhythm Management senior vice-president Randel Woodgrift said: “We are focused on developing and delivering life-changing technologies that impact patient care in a meaningful way.

“The Gallant devices are the latest example of how Abbott is driving innovation to meet changing healthcare needs and helping to improve connectivity and engagement between patients and their doctors.”

Earlier in February, Abbott obtained CE Mark for Gallant ICD and CRT-D devices in Europe.

Last month, the company reported a positive outcome for its optical coherence tomography (OCT) imaging techniques based on the data generated by the LightLab Initiative.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU